Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
Steady: 0 in the last 7 days
Updated sep 15
The latest in this situation
How it started
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- AstraZeneca's drug was tested in collaboration with Pfizer's drug.Sub-event
- Pfizer acquired Biohaven Pharmaceuticals, Seagen, and Arena Pharmaceuticals in transactions dating back to 2022.Sub-event
- Pfizer acquired Seagen for its cancer drug candidates, while a separate deal with Innovent helps offset revenue decline.Sub-event
- Certara and Merck announced an expansion of their clinical technology collaboration, which began on July 8, 2025.Sub-event
- Pfizer strengthens oncology position via Seagen acquisition; AZ forms new partnerships with Daiichi and Merck.
Keep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
AstraZeneca
British-Swedish pharmaceutical company
- AstraZeneca presented trial results for its IMFINZI cancer treatment at the European Society for Medical Oncology (ESMO) Congress in Madrid.
- Geopolitical instability in the Middle East has led to significant corporate fallout, including the cancellation of Flutter's London Stock Exchange listing and AstraZeneca considering a move to the US market.
-
Merck
public company in Indonesia
Related events
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- BioNTech announced new partnerships with Genmab, Pfizer, Bristol-Myers Squibb, and Genentech.
- AstraZeneca and Tarsus Pharmaceuticals, Inc. are two healthcare companies that are currently competing for investment.
- Replimune Group received FDA accelerated approval, and Mestag Therapeutics appointed new board members, including Victor Sandor and Philip Astley-Sparke.
- AstraZeneca and Tvardi Therapeutics are being compared as healthcare companies.
Coverage
Newest first; wire copies grouped- mmm-online.com
- Unknown outlet
- Unknown outlet